SCHEMBL7121362

SCHEMBL7121362

CCCc1c(Br)c2cc(Cl)ccc2[nH]c1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT1 Q96EB6 4/20 0.55
TSHR P16473 1/20 0.52
HSD17B10 Q99714 1/20 0.52
RAB9A P51151 1/20 0.48
ALDH1A1 P00352 2/20 0.47
MAPT P10636 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
HPGD P15428 2/20 0.47
KDM4E B2RXH2 1/20 0.47
HTT P42858 1/20 0.46
ADORA1 P30542 1/20 0.45
LMNA P02545 1/20 0.45
CYP1A2 P05177 2/20 0.44
GAA P10253 1/20 0.44
ROCK2 O75116 1/20 0.44
MAP4K4 O95819 1/20 0.44
LCK P06239 1/20 0.44
CSF1R P07333 1/20 0.44
PIM1 P11309 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7120398 0.88 SIRT1 (0.46) SIRT1TSHRHSD17B10RAB9AALDH1A1
SCHEMBL7116460 0.83 ALDH1A1 (0.65) SIRT1TSHRHSD17B10RAB9AALDH1A1
SCHEMBL7549839 0.80 ALDH1A1 (0.51) SIRT1TSHRHSD17B10ALDH1A1MAPT
SCHEMBL13979604 0.76 SIRT1 (0.68) SIRT1MEN1KMT2AHTR6L3MBTL1
SCHEMBL7124929 0.76 SIRT1 (0.46) SIRT1TSHRHSD17B10RAB9AALDH1A1
SCHEMBL7114914 0.76 SIRT1 (0.46) SIRT1TSHRHSD17B10RAB9AALDH1A1
SCHEMBL7116744 0.76 SIRT1 (0.46) SIRT1TSHRHSD17B10RAB9AALDH1A1
SCHEMBL7124010 0.75 SIRT1 (0.45) SIRT1TSHRHSD17B10RAB9AALDH1A1
SCHEMBL7116100 0.75 SIRT1 (0.45) SIRT1TSHRHSD17B10RAB9AALDH1A1
SCHEMBL28787087 0.74 LMNA (0.56) SIRT1RAB9AMEN1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030069271-A1 Quinolone compounds for use in treating viral infections SMITHKLINE BEECHAM CORPORATION 2003-04-10 US disclosed
EP-1244629-A2 QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2002-10-02 EP disclosed
WO-2001046150-A2 QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2001-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069271-A1 Quinolone compounds for use in treating viral infections IRF3, MAVS, NQO2 SIRT1 722/4885TSHR 4728/4885HSD17B10 1601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.